Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality 24% Improvement Relative Risk Hospitalization 20% HCQ  Landsteiner de Sampaio Amêndola et al.  META ANALYSIS c19hcq.org Favors HCQ Favors control

COVID-19 Infection in Rheumatic Patients on Chronic Antimalarial Drugs: A Systematic Review and Meta-Analysis

Landsteiner de Sampaio Amêndola et al., Journal of Clinical Medicine, doi:10.3390/jcm11226865
Nov 2022  
  Post
  Facebook
Share
  Source   PDF   All   Meta
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
 
*, now known with p < 0.00000000001 from 421 studies, recognized in 42 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,800+ studies for 60+ treatments. c19hcq.org
Systematic review and meta analysis of 20 studies on HCQ use in rheumatic disease patients, showing significantly lower mortality and hospitalization with HCQ prophylaxis.
7 meta analyses show significant improvements with hydroxychloroquine for mortality Landsteiner de Sampaio Amêndola, Risch, Risch (B), Stricker, hospitalization Landsteiner de Sampaio Amêndola, recovery Prodromos, combined death/hospitalization/cases Ladapo, and cases García-Albéniz.
Currently there are 106 HCQ for COVID-19 pre-exposure prophylaxis studies, showing 30% lower mortality [14‑43%] and 28% fewer cases [20‑35%].
risk of death, 24.0% lower, OR 0.76, p = 0.010, RR approximated with OR.
risk of hospitalization, 20.0% lower, OR 0.80, p = 0.04, RR approximated with OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Landsteiner de Sampaio Amêndola et al., 21 Nov 2022, peer-reviewed, 5 authors. Contact: isa.lands@hotmail.com (corresponding author).
This PaperHCQAll
COVID-19 Infection in Rheumatic Patients on Chronic Antimalarial Drugs: A Systematic Review and Meta-Analysis
Isabela Landsteiner De Sampaio Amêndola, Jonathan Aires Pinheiro, Pedro Póvoa, Vicente Cés De Souza Dantas, Rodrigo Bernardo Serafim
Journal of Clinical Medicine, doi:10.3390/jcm11226865
The ongoing chronic use of hydroxychloroquine or chloroquine (HCQ/CQ) in rheumatic patients might impact their outcomes after a SARS-CoV-2 infection. Therefore, we sought to assess the mortality in rheumatic patients with chronic HCQ/CQ use who developed a COVID-19 infection through a comparison between individuals chronically using HCQ/CQ with those not taking these drugs. We performed a systematic review and meta-analysis of studies on PubMed, Embase, and Cochrane Central. We included full-length reports, prospective observational cohorts, and clinical trials of adult patients (aged ≥ 18 years) who were diagnosed with a COVID-19 infection. Case studies, case series, letters, comments, and editorials were excluded. The main outcome was all-cause mortality. This study is registered with PROSPERO (CRD42022341678). We identified 541 studies, of which 20 studies were included, comprising 236,997 patients. All-cause mortality was significantly lower in patients with prior chronic use of HCQ/CQ compared to those with no previous usage (OR 0.76; 95% CI 0.62-0.94; p = 0.01). There was a considerably lower incidence of hospitalization among patients with chronic HCQ/CQ use compared to their counterparts without HCQ/CQ usage (OR 0.80; 95% CI 0.65-0.99; p = 0.04). All-cause mortality and hospitalization were significantly lower in rheumatic patients with chronic HCQ/CQ use who developed a COVID-19 infection.
Appendix B Duration of HCQ/CQ treatment Duration of HCQ/CQ treatment reported in the studies: Appendix D Sensitivity Analysis A sensitivity analysis was executed by sequentially deleting each study and reanalyzing the pooled estimate for the remaining studies. The sensitivity analysis for the outcome of all-cause mortality did not show any noteworthy difference when deleting any of its studies. However, concerning the hospitalization outcome, the Ugarte-Gil study demonstrated a substantial influence on the pooled OR. Following the exclusion of this study, the pooled OR became 1.15 (95% CI 0.79-1.69; p = 0.46; I 2 = 0%). When it came to excluding any other study related to the hospitalization outcome, there was no significant impact on the OR result. Appendix F The meta-regression performed on the outcome of all-cause mortality related to the mean age of patients and the one related to the proportion of men showed a Chi 2 = 1.28, df = 7, Sig. = 0.989. The meta-regression on the outcome of hospitalization related to the mean age showed a Chi 2 = 2.65, df = 10, Sig. = 0.989. The one performed for the proportion of men resulted in a Chi 2 = 6.22, df = 10, Sig. = 0.797. Appendix G Forest Plots with Fixed-Effect Appendix F The meta-regression performed on the outcome of all-cause mortality related to the mean age of patients and the one related to the proportion of men showed a Chi 2 = 1.28, df = 7, Sig. = 0.989. The meta-regression on the outcome of hospitalization..
References
Abarientos, Sperber, Shapiro, Aronow, Chao et al., Hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis and its safety in pregnancy, Expert Opin. Drug Saf, doi:10.1517/14740338.2011.566555
Ali, Abdel-Rahman, Almalikil, Mohamed, Alfaifi et al., Optimizing the Use of Hydroxychloroquine in the Management of COVID-19 Given Its Pharmacological Profile, J. Pharm. Res. Int
Alzahrani, Alghamdi, Almaqati, Clinical characteristics and outcome of COVID-19 in patients with rheumatic diseases, Rheumatol. Int, doi:10.1007/s00296-021-04857-9
Arshad, Pertinez, Box, Tatham, Rajoli et al., Prioritization of Anti-SARS-CoV-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics, Clin. Pharmacol. Ther, doi:10.1002/cpt.1909
Bagnall, The value of Chloroquine in rheumatoid disease: A four-year study of continuous therapy, Can. Med. Assoc. J
Batıbay, Ulucaköy, Özdemir, Günendi, Gö Güş, Clinical outcomes of Covid-19 in patients with rheumatic diseases and the effects of the pandemic on rheumatology outpatient care: A single-centre experience from Turkey, Int. J. Clin. Pract, doi:10.1111/ijcp.14442
Browning, Pharmacology of Chloroquine and Hydroxychloroquine, doi:10.1007/978-1-4939-0597-3_2
Chen, Hu, Zhang, Jiang, Han et al., Efficacy of Hydroxychloroquine in Patients with COVID-19: Results of a Randomized Clinical Trial, MedRxiv, doi:10.1101/2020.03.22.20040758
Derendorf, Excessive lysosomal ion-trapping of hydroxychloroquine and azithromycin, Int. J. Antimicrob. Agents, doi:10.1016/j.ijantimicag.2020.106007
Espinosa, Prieto-González, Llevadot, Marco-Hernández, Martínez-Artuña et al., The impact of SARS-CoV-2 coronavirus infection in patients with systemic lupus erythematosus from a single center in Catalonia, Clin. Rheumatol, doi:10.1007/s10067-021-05675-x
Eviatar, Elalouf, Furer, Goldstein-Lahat, Paran et al., Prevalence of COVID-19 and seroprevalence to SARS-CoV-2 in a rheumatologic patient population from a tertiary referral clinic in Israel, Intern. Med. J, doi:10.1111/imj.15202
Fernandez-Ruiz, Masson, Kim, Myers, Haberman et al., COVID-19 in Patients with Systemic Lupus Erythematosus, Arthritis Rheumatol, doi:10.1002/art.41450
Friedrich, Adhikari, Beyene, Inclusion of zero total event trials in meta-analyses maintains analytic consistency and incorporates all available data, BMC Med. Res. Methodol, doi:10.1186/1471-2288-7-5
Gao, Tian, Yang, Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies, Biosci. Trends, doi:10.5582/bst.2020.01047
Geleris, Sun, Platt, Zucker, Baldwin et al., Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19, N. Engl. J. Med, doi:10.1056/NEJMoa2012410
Gentry, Humphrey, Thind, Hendrickson, Kurdgelashvili et al., Long-term hydroxychloroquine use in patients with rheumatic conditions and development of SARS-CoV-2 infection: A retrospective cohort study, Lancet Rheumatol, doi:10.1016/S2665-9913(20)30305-2
Guan, Liang, Zhao, Liang, Chen et al., Comorbidity and its impact on 1590 patients with COVID-19 in China: A nationwide analysis, Eur. Respir. J, doi:10.1183/13993003.00547-2020
Guan, Liang, Zhao, Liang, Chen et al., Comorbidity and its impact on 1590 patients with COVID-19 in China: A nationwide analysis, Eur. Respir. J, doi:10.1183/13993003.00547-2020
Guan, Liang, Zhao, Liang, Chen et al., Comorbidity and its impact on 1590 patients with COVID-19 in China: A nationwide analysis, Eur. Respir. J, doi:10.1183/13993003.00547-2020
Guan, Liang, Zhao, Liang, Chen et al., Comorbidity and its impact on 1590 patients with COVID-19 in China: A nationwide analysis, Eur. Respir. J, doi:10.1183/13993003.00547-2020
Guillaume, Magalie, Sina, Imène, Frédéric et al., Antirheumatic Drug Intake Influence on Occurrence of COVID-19 Infection in Ambulatory Patients with Immune-Mediated Inflammatory Diseases: A Cohort Study, Rheumatol. Ther, doi:10.1007/s40744-021-00373-1
Harbord, Egger, Sterne, A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints, Stat. Med, doi:10.1002/sim.2380
Higgins, Thompson, Deeks, Altman, Measuring inconsistency in meta-analyses, BMJ, doi:10.1136/bmj.327.7414.557
Horby, Mafham, Linsell, Bell, Staplin et al., Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19, N. Engl. J. Med, doi:10.1056/NEJMoa2022926
Jung, Kim, Kim, Choi, Chung et al., Effect of hydroxychloroquine pre-exposure on infection with SARS-CoV-2 in rheumatic disease patients: A population-based cohort study, Clin. Microbiol. Infect, doi:10.1016/j.cmi.2020.12.003
Kim, Kwak, Lee, Kim, Choe et al., Baseline use of hydroxychloroquine or immunosuppressive drugs and the risk of coronavirus disease 2019, Korean J. Intern. Med, doi:10.3904/kjim.2020.633
Liu, Cao, Xu, Wang, Zhang et al., Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro, Cell Discov, doi:10.1038/s41421-020-0156-0
Liu, Maruyama, Masuda, Honda, Arai, The Influence of Virus Infection on the Extracellular pH of the Host Cell Detected on Cell Membrane, Front. Microbiol, doi:10.3389/fmicb.2016.01127
Mackenzie, Pharmacologic actions of 4-aminoquinoline compounds, Am. J. Med, doi:10.1016/0002-9343(83)91264-0
Macías, González-Moreno, Sánchez-García, Morillo-Verdugo, Pérez-Venegas et al., Similar incidence of coronavirus disease 2019 (COVID-19) in patients with rheumatic diseases with and without hydroxychloroquine therapy, PLoS ONE, doi:10.1371/journal.pone.0249036
Mohanasundaram, Annamalai, Santhanam, Nambi, Sankaran et al., COVID-19 and Rheumatic Diseases in Tamil Nadu-A multicenter retrospective observational study, Indian J. Rheumatol, doi:10.4103/injr.injr_327_20
Montero, Martínez-Barrio, Serrano-Benavente, González, Rivera et al., Coronavirus disease 2019 (COVID-19) in autoimmune and inflammatory conditions: Clinical characteristics of poor outcomes, Rheumatol. Int, doi:10.1007/s00296-020-04676-4
Munster, Gibbs, Shen, Baethge, Botstein et al., Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis, Arthritis Rheum, doi:10.1002/art.10307
Napoli, Nioi, Global Spread of Coronavirus Disease 2019 and Malaria: An Epidemiological Paradox in the Early Stage of a Pandemic, J. Clin. Med, doi:10.3390/jcm9041138
Osei, Biney, Anning, Nortey, Ghartey-Kwansah, Low incidence of COVID-19 case severity and mortality in Africa; Could malaria co-infection provide the missing link?, BMC Infect. Dis, doi:10.1186/s12879-022-07064-4
Pham, Torres, Satlin, Goyal, Gulick, Failure of chronic hydroxychloroquine in preventing severe complications of COVID-19 in patients with rheumatic diseases, Rheumatol. Adv. Pract, doi:10.1093/rap/rkab014
Ramirez, Gerosa, Beretta, Bellocchi, Argolini et al., COVID-19 in systemic lupus erythematosus: Data from a survey on 417 patients, Semin. Arthritis Rheum, doi:10.1016/j.semarthrit.2020.06.012
Rentsch, Devito, Mackenna, Morton, Bhaskaran et al., Effect of pre-exposure use of hydroxychloroquine on COVID-19 mortality: A population-based cohort study in patients with rheumatoid arthritis or systemic lupus erythematosus using the OpenSAFELY platform, Lancet Rheumatol, doi:10.1016/S2665-9913(20)30378-7
Rosenberg, Dufort, Udo, Wilberschied, Kumar et al., Association of Treatment with Hydroxychloroquine or Azithromycin with In-Hospital Mortality in Patients With COVID-19 in New York State, JAMA, doi:10.1001/jama.2020.8630
Scherbel, Harrison, Atdjian, Further observations on the use of 4-Aminoquinoline compounds in patients with rheumatoid arthritis or related diseases, Clevel. Clin. Q, doi:10.3949/ccjm.25.2.95
Self, Semler, Leither, Casey, Angus et al., Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19, JAMA, doi:10.1001/jama.2020.22240
Stewart, Clarke, Rovers, Riley, Simmonds et al., Preferred Reporting Items for a Systematic Review and Meta-analysis of Individual Participant Data: The PRISMA-IPD statement, JAMA, doi:10.1001/jama.2015.3656
Strangfeld, Schäfer, Gianfrancesco, Lawson-Tovey, Liew et al., Factors associated with COVID-19-related death in people with rheumatic diseases: Results from the COVID-19 Global Rheumatology Alliance physician-reported registry, Ann. Rheum. Dis, doi:10.1136/annrheumdis-2020-219498
Strangfeld, Schäfer, Gianfrancesco, Lawson-Tovey, Liew et al., Factors associated with COVID-19-related death in people with rheumatic diseases: Results from the COVID-19 Global Rheumatology Alliance physician-reported registry, Ann. Rheum. Dis, doi:10.1136/annrheumdis-2020-219498
Strangfeld, Schäfer, Gianfrancesco, Lawson-Tovey, Liew et al., Factors associated with COVID-19-related death in people with rheumatic diseases: Results from the COVID-19 Global Rheumatology Alliance physician-reported registry, Ann. Rheum. Dis, doi:10.1136/annrheumdis-2020-219498
Strangfeld, Schäfer, Gianfrancesco, Lawson-Tovey, Liew et al., Factors associated with COVID-19-related death in people with rheumatic diseases: Results from the COVID-19 Global Rheumatology Alliance physician-reported registry, Ann. Rheum. Dis, doi:10.1136/annrheumdis-2020-219498
Sweeting, Sutton, Lambert, What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data, Stat. Med, doi:10.1002/sim.1761
Teboh-Ewungkem, Ngwa, COVID-19 in malaria-endemic regions: Potential consequences for malaria intervention coverage, morbidity, and mortality, Lancet Infect. Dis, doi:10.1016/S1473-3099(20)30763-5
Tett, Cutler, Day, Antimalarials in rheumatic diseases, Baillieres Clin. Rheumatol, doi:10.1016/S0950-3579(05)80004-4
Tett, Cutler, Day, Brown, A dose-ranging study of the pharmacokinetics of hydroxy-chloroquine following intravenous administration to healthy volunteers, Br. J. Clin. Pharmacol, doi:10.1111/j.1365-2125.1988.tb05281.x
Trefond, Drumez, Andre, Costedoat-Chalumeau, Seror et al., Effet d'un traitement par hydroxychloroquine prescrit comme traitement de fond de rhumatismes inflammatoires chroniques ou maladies auto-immunes systémiques sur les tests diagnostiques et l'évolution de l'infection à SARS-CoV-2: Étude de 871 patients, Rev. Rhum. Ed. Fr, doi:10.1016/j.rhum.2021.09.004
Ugarte-Gil, Alarcón, Izadi, Duarte-García, Reátegui-Sokolova et al., Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: Data from the COVID-19 Global Rheumatology Alliance, Ann. Rheum. Dis, doi:10.1136/annrheumdis-2021-221636
Walbi, Albarqi, Alghanim, Albadi, Al Maimouni et al., Effect of chronic hydroxychloroquine use on COVID-19 risk in patients with rheumatoid arthritis and systemic lupus erythematosus: A multicenter retrospective cohort, J. Int. Med. Res, doi:10.1177/03000605221090363
Wang, Cao, Zhang, Yang, Liu et al., Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) In, Vitro. Cell Res, doi:10.1038/s41422-020-0282-0
Wells, Shea, O'connell, Peterson, Welch et al., The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses
Yao, Ye, Zhang, Cui, Huang et al., In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Clin. Infect. Dis, doi:10.1093/cid/ciaa237
Ye, Zhong, Cai, Dong, Li et al., COVID-19 infection in patients with connective tissue disease: A multicity study in Hubei province, China, MedComm, doi:10.1002/mco2.56
Yousefghahari, Navari, Sadeghi, Soleimaniamiri, Soleimaniamiri et al., Risk of COVID-19 infection in patients with rheumatic disease taking disease-modifying anti-rheumatic drugs, Clin. Rheumatol, doi:10.1007/s10067-021-05779-4
Zhou, Dai, Tong, COVID-19: A recommendation to examine the effect of hydroxychloroquine in preventing infection and progression, J. Antimicrob. Chemother, doi:10.1093/jac/dkaa114
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit